BR0108401A - Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina - Google Patents

Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina

Info

Publication number
BR0108401A
BR0108401A BR0108401-1A BR0108401A BR0108401A BR 0108401 A BR0108401 A BR 0108401A BR 0108401 A BR0108401 A BR 0108401A BR 0108401 A BR0108401 A BR 0108401A
Authority
BR
Brazil
Prior art keywords
carboxamidine
modified
bicyclically
nucleoside analogs
based nucleoside
Prior art date
Application number
BR0108401-1A
Other languages
English (en)
Inventor
Robert Tam
Guangyi Wang
Zhi Hong
Johnson Lau
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Publication of BR0108401A publication Critical patent/BR0108401A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Abstract

"ANáLOGOS DE NUCLEOSìDEOS COM BASE BICìCLICA MODIFICADA POR CARBOXAMIDINA". A presente invenção refere-se a novos compostos de análogos de nucleosídeos. Os novos compostos ou ésteres ou sais farmaceuticamente aceitáveis dos mesmos poderão ser usados em composições farmacêuticas, e essas composições poderão ser usadas para tratar uma infecção, uma infestação, um neoplasma ou uma doença auto-imune. Os novos compostos poderão também ser usados para modular aspectos do sistema imune, incluindo modulação de atividades Tipo 1 e Tipo 2.
BR0108401-1A 2000-02-15 2001-02-15 Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina BR0108401A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18267600P 2000-02-15 2000-02-15
US09/595,365 US6455508B1 (en) 2000-02-15 2000-10-05 Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
PCT/US2001/005172 WO2001060381A1 (en) 2000-02-15 2001-02-15 Nucleoside analogs with carboxamidine-modified bicyclic base

Publications (1)

Publication Number Publication Date
BR0108401A true BR0108401A (pt) 2004-01-06

Family

ID=26878297

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0108402-0A BR0108402A (pt) 2000-02-15 2001-02-15 Análogos de nucleosìdeo com base monocìclica carboxamidina modificado
BR0108401-1A BR0108401A (pt) 2000-02-15 2001-02-15 Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0108402-0A BR0108402A (pt) 2000-02-15 2001-02-15 Análogos de nucleosìdeo com base monocìclica carboxamidina modificado

Country Status (29)

Country Link
US (1) US6455508B1 (pt)
EP (3) EP1278528A4 (pt)
JP (3) JP2004510691A (pt)
KR (2) KR100811927B1 (pt)
CN (2) CN1420779A (pt)
AT (1) ATE377422T1 (pt)
AU (2) AU3845001A (pt)
BR (2) BR0108402A (pt)
CA (2) CA2395854A1 (pt)
CY (1) CY1107103T1 (pt)
CZ (2) CZ20022799A3 (pt)
DE (1) DE60131250T8 (pt)
DK (1) DK1257281T3 (pt)
ES (2) ES2528429T3 (pt)
HK (1) HK1051149A1 (pt)
HR (2) HRP20020583A2 (pt)
HU (2) HU229480B1 (pt)
IL (3) IL150555A0 (pt)
MX (2) MXPA02007932A (pt)
NO (2) NO329927B1 (pt)
NZ (2) NZ520877A (pt)
PL (2) PL200140B1 (pt)
PT (1) PT1257281E (pt)
RS (1) RS20090086A (pt)
RU (2) RU2259831C2 (pt)
SI (2) SI21077A (pt)
SK (2) SK287765B6 (pt)
WO (2) WO2001060381A1 (pt)
YU (1) YU61502A (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US7056895B2 (en) * 2000-02-15 2006-06-06 Valeant Pharmaceuticals International Tirazole nucleoside analogs and methods for using same
US7638496B2 (en) * 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
EP1707571B1 (en) 2001-01-22 2011-09-28 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2003037908A1 (en) * 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
JP2006524227A (ja) * 2003-03-28 2006-10-26 ファーマセット，インク． フラビウイルス科ウイルス感染の治療のための化合物
US20040197292A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
US20040197287A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
US20040202636A1 (en) * 2003-04-11 2004-10-14 Kaczvinsky Joseph Robert Personal care composition containing an antidandruff component and a nonionic surfactant
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
US20050009848A1 (en) * 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
US20050095218A1 (en) * 2003-10-29 2005-05-05 The Procter & Gamble Company Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
MX2008001588A (es) 2005-08-01 2008-02-19 Merck & Co Inc Inhibidores de proteasa ns3 del vhc.
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
NZ569883A (en) * 2005-12-28 2011-12-22 Translational Therapeutics Inc Use of triazole containing compounds for inhibiting 4E activity and proliferation of a cell
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
WO2008051475A2 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8377873B2 (en) 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
CA2667032A1 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
AU2007335962B2 (en) 2006-12-20 2012-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
RU2466729C2 (ru) * 2006-12-28 2012-11-20 Айденикс Фармасьютикалз, Инк. Соединения и фармацевтические композиции для лечения вирусных инфекций
JP2010533698A (ja) 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎感染症の治療のための大環状インドール誘導体
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
EP2271345B1 (en) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
ES2491090T3 (es) 2008-07-22 2014-09-05 Merck Sharp & Dohme Corp. Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
WO2013074386A2 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
CN102978264B (zh) * 2012-11-14 2014-12-10 广东肇庆星湖生物科技股份有限公司 一种他立韦林的制备方法
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
CN106061984A (zh) 2014-02-13 2016-10-26 配体药物公司 前药化合物及其用途
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
EP3331895B1 (en) * 2015-08-06 2020-07-29 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
WO2019060692A1 (en) 2017-09-21 2019-03-28 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3991078A (en) 1971-06-01 1976-11-09 Icn Pharmaceuticals, Inc. N-substituted 1,2,4-triazoles
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3962211A (en) * 1975-01-13 1976-06-08 The University Of Utah 7-substituted nucleoside compounds
US4093624A (en) 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
JPS6426593A (en) 1987-07-21 1989-01-27 Asahi Glass Co Ltd Nucleoside derivative
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
SI9720013A (sl) * 1996-01-23 1999-06-30 Icn Pharmaceuticals, Inc. Uravnavanje ekspresije citokinov TH1/TH2 z ribavirinom in z analogi ribavirina v aktiviranih T-limfocitih
DE69721339T2 (de) * 1996-10-16 2004-01-22 Ribapharm, Inc., Costa Mesa Monozyklische l-nukleoside, analoga und ihre anwendungen
PL354094A1 (en) * 1999-08-27 2003-12-29 Icn Pharmaceuticals, Inc.Icn Pharmaceuticals, Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs

Also Published As

Publication number Publication date
PL357945A1 (en) 2004-08-09
CY1107103T1 (el) 2012-10-24
EP1278528A1 (en) 2003-01-29
NO20023855D0 (no) 2002-08-14
DE60131250D1 (de) 2007-12-20
ES2295148T3 (es) 2008-04-16
ES2528429T3 (es) 2015-02-09
EP1813278B1 (en) 2014-10-29
JP2004510691A (ja) 2004-04-08
NO20023855L (no) 2002-10-08
EP1257281B1 (en) 2007-11-07
RU2259831C2 (ru) 2005-09-10
SI21076A (sl) 2003-06-30
HRP20020657A2 (en) 2005-10-31
EP1813278B9 (en) 2015-04-01
SI21077A (sl) 2003-06-30
MXPA02007932A (es) 2004-10-15
ES2528429T9 (es) 2015-05-07
SK11572002A3 (sk) 2003-02-04
CA2399208C (en) 2010-04-13
DE60131250T2 (de) 2008-08-28
JP2004509061A (ja) 2004-03-25
NO20023852D0 (no) 2002-08-14
US6455508B1 (en) 2002-09-24
IL150990A0 (en) 2003-02-12
SK287765B6 (sk) 2011-09-05
CZ20022799A3 (cs) 2003-09-17
HUP0300027A3 (en) 2003-09-29
HUP0300912A2 (hu) 2003-08-28
JP4975930B2 (ja) 2012-07-11
CN1268335C (zh) 2006-08-09
NZ520877A (en) 2004-12-24
EP1257281A4 (en) 2003-03-19
DK1257281T3 (da) 2008-01-14
CN1420779A (zh) 2003-05-28
AU4798801A (en) 2001-08-27
YU61502A (sh) 2006-03-03
JP5253204B2 (ja) 2013-07-31
MXPA02007931A (es) 2004-10-15
AU3845001A (en) 2001-08-27
PL200140B1 (pl) 2008-12-31
CA2399208A1 (en) 2001-08-23
NO329927B1 (no) 2011-01-24
KR20030032917A (ko) 2003-04-26
KR100811927B1 (ko) 2008-03-10
EP1813278A1 (en) 2007-08-01
NO20023852L (no) 2002-10-09
RS20090086A (en) 2010-06-30
SK11492002A3 (sk) 2003-02-04
HRP20020583A2 (en) 2005-10-31
HU229480B1 (en) 2014-01-28
RU2002120483A (ru) 2004-01-27
EP1278528A4 (en) 2003-03-19
HUP0300027A2 (en) 2003-05-28
PL365239A1 (en) 2004-12-27
CZ20022798A3 (cs) 2003-03-12
PT1257281E (pt) 2007-12-11
WO2001060381A1 (en) 2001-08-23
EP1257281A1 (en) 2002-11-20
CN1438891A (zh) 2003-08-27
CA2395854A1 (en) 2001-08-23
RU2002120922A (ru) 2004-01-27
NZ521390A (en) 2004-05-28
JP2009102406A (ja) 2009-05-14
EP1257281B8 (en) 2008-01-23
IL150990A (en) 2009-05-04
WO2001060379A1 (en) 2001-08-23
WO2001060381B1 (en) 2001-11-01
AU783142B2 (en) 2005-09-29
DE60131250T8 (de) 2009-01-15
HK1051149A1 (en) 2003-07-25
IL150555A0 (en) 2003-02-12
CZ302327B6 (cs) 2011-03-16
BR0108402A (pt) 2003-03-11
ATE377422T1 (de) 2007-11-15
KR20030005190A (ko) 2003-01-17

Similar Documents

Publication Publication Date Title
BR0108401A (pt) Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
BR9803880A (pt) Derivados de pirazol, sua preparação e seu emprego em medicamentos.
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
BR9814956A (pt) Inibidores de benzotiazol da tirosina cinase de proteìna
PT979244E (pt) Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
BRPI0518861A2 (pt) compostos, sais ou hidratos farmaceuticamente aceitos, composição farmacêutica e métodos de modulação de atividades imuno das citocinas e de tratamento da infecção por vìrus da hepatite c em paciente
PT1115417E (pt) Utilizacao da daptomicina
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
DE69027031T2 (de) Nicht glycosierte proteine, analoge des menschlichen interleukin-3
IT1187828B (it) Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
LV10186A (lv) Cistina atvasinajumu pielietojums arstniecibas lidzeklu ar imunomodulejosu darbibu pagatavosanai farmaceitiskas kompozicijas uz to bazes
BR9912218A (pt) Compostos obtidos de espécies de sálvia possuindo atividade antivirótica
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
DK0517986T3 (da) Transformerede erythrocytter, fremgangsmåde til fremstilling af samme og deres anvendelse i farmaceutiske præparater
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
BR0009476A (pt) Esteróides imunomoduladores, em particular hemidrato de 16 alfa-bromoepiandrosterona
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
BR0007991A (pt) Uso do composto ácido (e) -7- [ 4- (4-fluorofenil) -6-isopropil-2- [metil (metilsulfonil) amino] pirimidin -5-il] - (3r, 5s) -3,5-diidroxiept-6-enóico, ou de um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de preparação de uma composição farmacêutica, de redução dos nìveis de c-ldl e da razão de lipìdeo de c-ldl/ c-hdl, e, regime dosagem
ATE371737T1 (de) Proteaseresistente flint-analoge

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.